1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Session

Thumbnail for Does Minimal Residual Disease Negativity Overcome High-Risk Cytogenetics After Autologous Stem Cell Transplantation in Multiple Myeloma?

MM - 130

Does Minimal Residual Disease Negativity Overcome High-Risk Cytogenetics After Autologous Stem Cell Transplantation in Multiple Myeloma?

Rithika Manjunatha Reddy

Poster Presenter: Rithika Manjunatha Reddy

$Thumbnail for Facial Palsy Reports With BCMAΧCD3 and GPRC5DΧCD3 Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A FAERS Disproportionality Analysis$

MM - 1300

Facial Palsy Reports With BCMAΧCD3 and GPRC5DΧCD3 Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A FAERS Disproportionality Analysis

Bella Sajida

Poster Presenter: Bella Sajida

SOHO 2026 Annual Meeting

Posters by Session

Does Minimal Residual Disease Negativity Overcome High-Risk Cytogenetics After Autologous Stem Cell Transplantation in Multiple Myeloma?

Facial Palsy Reports With BCMAΧCD3 and GPRC5DΧCD3 Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A FAERS Disproportionality Analysis

NGS Based Assessments of Treatment Response in Patients With Multiple Myeloma Treated With Bispecific T Cell Engagers

Beyond a Single Entity: Site-Specific Heterogeneity in Clinical Characteristics, Treatment Patterns, and Survival Outcomes Among Patients With Plasmacytoma

Clinical Landscape and Prognostic Impact of Extramedullary Disease in Multiple Myeloma: A Large Single-Center Retrospective Analysis

Mortality, Thrombotic, Hemorrhagic, and Cardiovascular Outcomes With First-Line Carfilzomib Versus Bortezomib in Adults With Multiple Myeloma: A Real-World Propensity-Matched Analysis

Prophylactic Tocilizumab To Reduce the Risk of CRS and ICANS in Patients With Relapsed/Refractory Multiple Myeloma Treated With Elranatamab

Multiple Myeloma Management in North Africa: Real-World Evidence and Outcomes From a 140 Patient Tunisian Cohort

Durable Clinical Benefit of B-Cell Maturation Antigen (BCMA)-Directed Therapy With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (BPd) in Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-8 Long-Term Responder (LTR) Analysis